It has been reported that fucoidan (OF) can bind to the asialoglycoprotein receptor (ASGR) in liver cancer cells, promoting the binding of transcription activator 3 (STAT3) to the P1 promoter of hepatocyte nuclear factor 4A (HNF4A), inducing the expression of P1-HNF4A, and inhibiting the proliferation of cancer cells (Wu et al., 2020). This evidence concerns the gene HNF4A and liver cancer.